Tiragolumab
- Generic Name
- Tiragolumab
- Drug Type
- Biotech
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: Granulocyte colony-stimulating factor (G-CSF)Drug: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT04584112
- Locations
- 🇺🇸
Tennessee Onc., PLLC - SCRI, Nashville, Tennessee, United States
🇦🇺Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia
🇧🇷Hospital Sírio-Libanês, Sao Paulo, SP, Brazil
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 760
- Registration Number
- NCT04543617
- Locations
- 🇵🇹
Centro Hospitalar do Porto ? Hospital de Santo António, Porto, Portugal
🇵🇹IPO do Porto, Porto, Portugal
🇿🇦Eugene Marais Hospital, Pretoria, South Africa
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 461
- Registration Number
- NCT04540211
- Locations
- 🇨🇳
Nan Tong Tumor Hospital, Nantong City, China
🇨🇳Anhui Provincial Hospital, Anhui, China
🇨🇳Anyang Tumor Hosptial, Anyang City, China
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Conditions
- Advanced Liver Cancers
- Interventions
- Drug: IO-108 1800 mgDrug: Tobemstomig 2100 mgDrug: Tobemstomig 600 mgDrug: Tobemstomig 1200 mgDrug: IO-108 1200 mg
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- 🇮🇱
Hadassah University Medical Center, Jerusalem, Israel
🇰🇷CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of
🇺🇸University of California San Diego, La Jolla, California, United States
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 829
- Registration Number
- NCT04513925
- Locations
- 🇫🇷
Clinique Clémentville, Montpellier, France
🇫🇷Hopital Robert Schuman, Vantoux, France
🇰🇷Ulsan University Hosiptal, Ulsan, Korea, Republic of
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 148
- Registration Number
- NCT04486352
- Locations
- 🇺🇸
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Englewood Health, Englewood, New Jersey, United States
🇺🇸Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- Conditions
- Carcinoma, Small Cell Lung
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT04308785
- Locations
- 🇨🇳
Anhui Province Cancer Hospital, Hefei City, China
🇨🇳Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT04300647
- Locations
- 🇮🇹
Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy
🇵🇦Centro Oncológico de Panamá, Panama, Panama
🇵🇦The Panama Clinic, Panama, Panama
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 620
- Registration Number
- NCT04294810
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇨🇭Inselspital Bern, Bern, Switzerland
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT04256421
- Locations
- 🇩🇪
LungenClinic Großhansdorf GmbH, Großhansdorf, Germany
🇵🇱Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, Poland
🇹🇷Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.